Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome

E-ISSN： 1875-5607|16|18|1462-1469

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.16, Iss.18, 2016-12, pp. : 1462-1469

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Review of tegaserod in the treatment of irritable bowel syndrome

By Patel Sonal Berrada Driss Lembo Anthony

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 11, 2004-11 ,pp. : 2369-2379

Informa Healthcare

Access to resources Recommend Favorite

Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome

By Camilleri Michael

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1151-1160

Informa Healthcare

Access to resources Recommend Favorite

Rifaximin for the treatment of irritable bowel syndrome

By Cremonini Filippo Lembo Anthony

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 3, 2012-02 ,pp. : 433-440

Informa Healthcare

Access to resources Recommend Favorite

Asimadoline in the treatment of irritable bowel syndrome

By Mangel Allen W Williams Valerie SL

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 10, 2010-10 ,pp. : 1257-1264

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review

Current Drug Targets, Vol. 19, Iss. 15, 2018-12 ,pp. : 1774-1781

Bentham Science Publishers

Access to resources Recommend Favorite